SCYNEXIS Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

SCYNEXIS wird ein Gewinn- und Umsatzwachstum von 48.7% bzw. 30.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 49.2% pro Jahr wachsen soll.

Wichtige Informationen

48.7%

Wachstumsrate der Gewinne

49.2%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	19.6%
Wachstumsrate der Einnahmen	30.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	07 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

LSE:0L49 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	111	65	17	40	4
12/31/2025	53	8	N/A	12	4
12/31/2024	10	-22	N/A	-14	4
9/30/2024	9	-36	-22	-22	N/A
6/30/2024	10	-35	-10	-10	N/A
3/31/2024	140	101	75	75	N/A
12/31/2023	140	67	60	60	N/A
9/30/2023	136	72	45	45	N/A
6/30/2023	136	44	10	10	N/A
3/31/2023	6	-91	-83	-83	N/A
12/31/2022	5	-63	-80	-80	N/A
9/30/2022	4	-78	-83	-83	N/A
6/30/2022	3	-49	-78	-77	N/A
3/31/2022	2	-34	-71	-70	N/A
12/31/2021	13	-33	-56	-55	N/A
9/30/2021	13	-46	-46	-46	N/A
6/30/2021	12	-45	-39	-39	N/A
3/31/2021	12	-53	-36	-36	N/A
12/31/2020	N/A	-55	-49	-49	N/A
9/30/2020	N/A	-27	-46	-46	N/A
6/30/2020	N/A	-36	-47	-47	N/A
3/31/2020	0	-38	-46	-46	N/A
12/31/2019	0	-54	-38	-38	N/A
9/30/2019	0	-37	-31	-31	N/A
6/30/2019	0	-29	-27	-26	N/A
3/31/2019	0	-31	-27	-27	N/A
12/31/2018	0	-12	-29	-28	N/A
9/30/2018	0	-22	-28	-27	N/A
6/30/2018	0	-31	N/A	-27	N/A
3/31/2018	0	-24	N/A	-26	N/A
12/31/2017	0	-25	N/A	-25	N/A
9/30/2017	0	-21	N/A	-24	N/A
6/30/2017	0	-24	N/A	-26	N/A
3/31/2017	0	-28	N/A	-27	N/A
12/31/2016	0	-30	N/A	-29	N/A
9/30/2016	0	-35	N/A	-31	N/A
6/30/2016	0	-31	N/A	-30	N/A
3/31/2016	0	-30	N/A	-29	N/A
12/31/2015	0	-28	N/A	-25	N/A
9/30/2015	1	-23	N/A	-20	N/A
6/30/2015	1	-19	N/A	-18	N/A
3/31/2015	1	-11	N/A	-14	N/A
12/31/2014	1	-7	N/A	-9	N/A
9/30/2014	4	-42	N/A	-9	N/A
6/30/2014	8	-43	N/A	-6	N/A
3/31/2014	12	-47	N/A	-2	N/A
12/31/2013	17	-47	N/A	-4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 0L49 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.1%).

Ertrag vs. Markt: 0L49 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: 0L49 wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: 0L49Die Einnahmen des Unternehmens (30.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (3.6% pro Jahr).

Hohe Wachstumseinnahmen: 0L49Die Einnahmen des Unternehmens (30.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 0L49 in 3 Jahren voraussichtlich hoch sein wird

SCYNEXIS Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast breakeven date moved forward to 2023

Forecast to breakeven in 2025

Forecast to breakeven in 2025

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2024

Recent updates

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. to Report Q3, 2024 Results on Oct 18, 2024

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$2.56 profit in 2Q 2023)

First quarter 2024 earnings released: EPS: US$0.009 (vs US$0.71 loss in 1Q 2023)

New major risk - Revenue and earnings growth

SCYNEXIS, Inc., Annual General Meeting, Jun 19, 2024

SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases

New major risk - Share price stability

Full year 2023 earnings released: EPS: US$1.40 (vs US$1.47 loss in FY 2022)

Bronstein, Gewirtz & Grossman LLC Announces SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Third quarter 2023 earnings released: US$0.037 loss per share (vs US$0.62 loss in 3Q 2022)

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

SCYNEXIS, Inc. Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology

SCYNEXIS, Inc. Issues A Voluntary Nationwide Recall of BREXAFEMME® (Ibrexafungerp Tablets) Due to Potential for Cross Contamination with A Non-Antibacterial ß-Lactam Drug Substance

Investor sentiment deteriorates as stock falls 33%

Investor sentiment deteriorates as stock falls 16%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: US$2.56 (vs US$0.31 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.71 loss per share (vs US$0.17 loss in 1Q 2022)

Forecast breakeven date moved forward to 2023

Forecast to breakeven in 2025

Insufficient new directors

Forecast to breakeven in 2025

Scynexis AnnouncesFDA Approval of Second Indication for Brexafemme® (Ibrexafungerp Tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

Insufficient new directors

SCYNEXIS, Inc. Announces Positive Results from Pooled Analysis of Two Phase 3 Studies (VANISH-303 and VANISH-306) in the Journal of Women’s Health

SCYNEXIS, Inc. to Report Q3, 2022 Results on Nov 09, 2022

SCYNEXIS, Inc. Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022

SCYNEXIS, Inc. Announces CEO Changes

Insufficient new directors

SCYNEXIS, Inc. Presents Positive Interim Data of ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.064 profit in 2Q 2021)

SCYNEXIS, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting

SCYNEXIS, Inc. Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME

Scynexis Presents Positive Data from Phase 3 Candle Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the Issvd Xxvi World Congress and International Vulvovaginal Disease Update

Insufficient new directors

Insufficient new directors

Scynexis Announces Initiation of New Phase 3B Study (Vanquish) to Evaluate Oral Ibrexafungerp as A Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole

SCYNEXIS, Inc. Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections

SCYNEXIS, Inc., Annual General Meeting, Jun 16, 2022

SCYNEXIS, Inc. Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

SCYNEXIS, Inc. to Report Q1, 2022 Results on May 12, 2022

No longer forecast to breakeven

Insufficient new directors

SCYNEXIS, Inc. has completed a Follow-on Equity Offering in the amount of $44.988333 million.

SCYNEXIS, Inc. Announces Positive Interim Data from its Ongoing Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections

No longer forecast to breakeven

SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections

Insufficient new directors

Forecast to breakeven in 2024

SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis

Scynexis, Inc. Announces Peer-Reviewed Publication of Results

Scynexis, Inc. Announces U.S. Availability of BREXAFEMME®

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken